<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00147251</url>
  </required_header>
  <id_info>
    <org_study_id>2000-285</org_study_id>
    <secondary_id>Grant # 1 U01 HL67031</secondary_id>
    <nct_id>NCT00147251</nct_id>
    <nct_alias>NCT00047424</nct_alias>
  </id_info>
  <brief_title>Stop Atherosclerosis in Native Diabetics Study</brief_title>
  <acronym>SANDS</acronym>
  <official_title>Stop Atherosclerosis in Native Diabetics Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cynthia West</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medstar Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compared to standard treatment goals achieving lower targets for LDL cholesterol (bad&#xD;
      cholesterol) and blood pressure in people with diabetes will slow the progression of&#xD;
      atherosclerosis as measured by carotid artery thickness, and reduce clinical cardiovascular&#xD;
      events such as heart attacks and strokes. This study is a randomized 3-year trial. The&#xD;
      primary endpoint will be a combination of various measures of the carotid artery, (which is&#xD;
      an easy, non-invasive way to detect cardiovascular disease) and events such as heart attacks&#xD;
      and strokes. The study will also look at secondary endpoints such as how well the heart&#xD;
      pumps, fat,protein and inflammatory markers in the blood,and kidney function. The study&#xD;
      enrolled 549 American Indian men and women with diabetes, &gt; 40 years of age and is being&#xD;
      conducted in four field centers involving Indian Health Service/Tribal primary care&#xD;
      facilities in Phoenix/Sacaton, Arizona; Chinle, Arizona; Rapid City/Pine Ridge, South Dakota;&#xD;
      and Lawton, Oklahoma, with input from American Indian physicians and community members.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetes incidence is increasing rapidly in the United States. Diabetes increases the risk&#xD;
      for CVD, the major cause of death in diabetic individuals. The conventional cardiovascular&#xD;
      risk factors of hyperlipidemia and hypertension add to the progression of diabetic vascular&#xD;
      disease. Appropriate treatment targets for LDL-C and blood pressure in diabetic individuals&#xD;
      are currently being debated. The Stop Atherosclerosis in Native Diabetics Study is a&#xD;
      randomized, open label, 3-year, clinical trial to examine the effects of aggressive LDL-C&#xD;
      (goal &lt; 70 mg/dL) and BP (goal &lt; 115/75 mm Hg) reduction versus the standard goals of &lt; 100&#xD;
      mg/dL for LDL-C and &lt; 130/85 mmHg for BP. Five hundred forty-nine American Indian men and&#xD;
      women &gt; age 40 with type 2 diabetes were randomized to one of two groups. Lipids and BP are&#xD;
      managed using FDA-approved medications in an algorithmic approach. The presence and&#xD;
      progression of atherosclerosis are evaluated by carotid ultrasonography; echocardiography&#xD;
      assesses cardiac function. The primary endpoint is the composite outcome of change in carotid&#xD;
      artery intimal medial thickness and fatal/nonfatal cardiovascular events. These outcomes are&#xD;
      combined by using a ranked analysis for carotid thickness and assigning a &quot;worst rank&quot; for a&#xD;
      cardiovascular event. Secondary endpoints include carotid plaque score, left ventricular&#xD;
      geometry and function, serum CRP, and safety measures. Unique aspects of the study design and&#xD;
      analysis plan involve changes during the trial of LDL-C treatment goals for participants with&#xD;
      baseline or incident CVD in the conventional group, because of changes in the standard of&#xD;
      care, and the use of a composite outcome. Study results will be valuable in understanding the&#xD;
      effects of aggressive risk factor reduction on atherosclerosis burden and cardiac function in&#xD;
      diabetic individuals in all U.S. populations and will provide evidence for determining&#xD;
      optimal LDL-C and BP treatment goals for diabetic patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">May 1, 2007</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changing LDL Cholesterol</measure>
    <time_frame>36 months</time_frame>
    <description>LDL cholesterol intervention to lower targets than are currently recommended to retard atherosclerosis measured by LDL-C mg/dL.&#xD;
Scale: LDL cholesterol levels should be less than 100 mg/dL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changing Blood Pressure</measure>
    <time_frame>36 month follow-up</time_frame>
    <description>Treatment of blood pressure to prevent/reduce diseases of heart and blood vessels. Measured by mmHG.&#xD;
Normal values should be below 120/80 mm Hg.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">548</enrollment>
  <condition>Cardiovascular Disease</condition>
  <condition>Hypertension</condition>
  <condition>Hyperlipidemia</condition>
  <condition>Diabetes</condition>
  <condition>Carotid Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>SANDS Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard Treatment for blood pressure and cholesterol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SANDS Intervention Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FDA approved drugs to treat blood pressure and cholesterol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FDA approved drugs to treat blood pressure and cholesterol</intervention_name>
    <arm_group_label>SANDS Intervention Group</arm_group_label>
    <other_name>No Intervention</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. American Indian men and women 40 years of age or older&#xD;
&#xD;
          2. Type 2 DM (according to 1997 ADA criteria and/or previously diagnosed by former ADA or&#xD;
             WHO criteria): fasting plasma glucose &gt;= 7.0 mmol/L (126 mg/dL) or 2-hour glucose &gt;=&#xD;
             11.0 mmol/L (&gt;200 mg/dL) after a 75-gram oral glucose tolerance test.&#xD;
&#xD;
          3. LDL cholesterol &gt;= 100 mg/dL. within the previous 12 months.&#xD;
&#xD;
          4. Systolic BP &gt;= 130 mm Hg. within the previous 12 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. New York Heart Association Stage III- IV congestive heart failure.&#xD;
&#xD;
          2. SBP &gt;180 mmHg (2% of population) or patients with known causes of hypertension.&#xD;
&#xD;
          3. History of angioedema.&#xD;
&#xD;
          4. Any medical condition that study physicians believe would interfere with study&#xD;
             participation or evaluation of results.&#xD;
&#xD;
          5. Mental incapacity and/or cognitive impairment on the part of the patient that would&#xD;
             preclude adequate understanding of, or cooperation with, the study protocol.&#xD;
&#xD;
          6. Serum hepatic transaminase levels 2X the upper limit of normal.&#xD;
&#xD;
          7. Participation in any clinical trial of any investigational medication within 3 months&#xD;
             prior to this trial.&#xD;
&#xD;
          8. Renal insufficiency as indicated by serum creatinine &gt;2.0 for women and &gt;2.4 for men.&#xD;
&#xD;
          9. Diagnosis of primary hyperlipidemia in medical record.&#xD;
&#xD;
         10. Secondary hypercholesterolemia due to hypothyroidism or nephrotic syndrome. Patients&#xD;
             on stable doses of thyroid replacement therapy will be eligible.&#xD;
&#xD;
         11. Presence of malignancy or history of any cancer except skin cancer within the past 5&#xD;
             years.&#xD;
&#xD;
         12. Pregnancy or lactation. Premenopausal women will be requested to use birth control&#xD;
             methods throughout the study and provided educational materials about the risks of&#xD;
             using the study medications during pregnancy.&#xD;
&#xD;
         13. Unable to obtain quantifiable carotid measure during screening examination.&#xD;
&#xD;
         14. Concomitant long term use of cyclosporins (Sandimmune), macrolide antibiotics&#xD;
             (erythromycin -many generic and brand name forms, clarithromycin, Biaxin, and&#xD;
             Zithromax), azole antifungals (itraconazole-Sporanox, ritonavir, Norvir, and&#xD;
             nelfinavir (Viracept).&#xD;
&#xD;
         15. Orthostatic hypotension as defined by the following:&#xD;
&#xD;
               1. The individual has a measured fall of &gt;20 mmHg in systolic BP upon standing&#xD;
                  associated with symptoms lasting more than one minute (or severe symptoms that&#xD;
                  would not allow further lowering of BP)&#xD;
&#xD;
               2. The standing systolic blood pressure is less than 90 mm.&#xD;
&#xD;
         16. Triglyceride level &gt;350 mg/dl.&#xD;
&#xD;
         17. Severe aortic stenosis with valve area &lt;=1.0 square cm.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara V Howard, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medstar Health Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chinle Comprehensive Health Care</name>
      <address>
        <city>Chinle</city>
        <state>Arizona</state>
        <zip>86503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Indian Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USPHS Indian Hospital</name>
      <address>
        <city>Lawton</city>
        <state>Oklahoma</state>
        <zip>73507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Black Hills Center for American Indian Health</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 2, 2005</study_first_submitted>
  <study_first_submitted_qc>September 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <results_first_submitted>August 30, 2018</results_first_submitted>
  <results_first_submitted_qc>June 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 7, 2021</results_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medstar Health Research Institute</investigator_affiliation>
    <investigator_full_name>Cynthia West</investigator_full_name>
    <investigator_title>Phoenix Field Office Manager</investigator_title>
  </responsible_party>
  <keyword>lowering LDL and BP below current targets</keyword>
  <keyword>LDL cholesterol treatment</keyword>
  <keyword>blood pressure treatment</keyword>
  <keyword>carotid intimal medial thickness</keyword>
  <keyword>prevent progression of CVD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Artery Diseases</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were identified from the local Indian hospital service center, or DM clinic. In March 2004, the DSMB recommended and the SC voted to over-recruit by 10-20% to compensate for the possible need for more aggressive treatment for participants with baseline CVD. Randomization concluded in July 2004 with 547 randomized participants.</recruitment_details>
      <pre_assignment_details>Sonogram eligibility was confirmed by tape review at the core lab prior to randomization. A potential participant had to have LDL-C &gt; 100 mg/dL and systolic BP &gt; 130/85 mmHg. A participant could undergo a maximum of four screening visits within a 3-month period to confirm eligibility.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard Treatment</title>
          <description>standard targets of LDL-C &lt; 100 mg/dL and BP &lt; 130/85 mm Hg</description>
        </group>
        <group group_id="P2">
          <title>Aggressive Treatment</title>
          <description>/aggressive targets of LDL-C &lt; 70 mg/dL plus BP &lt; 115/75 mm Hg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Recruitment and Enrollment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="271"/>
                <participants group_id="P2" count="277"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="247"/>
                <participants group_id="P2" count="252"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>change in treatment guidelines</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="247"/>
                <participants group_id="P2" count="252"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="247"/>
                <participants group_id="P2" count="252"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Treatment</title>
          <description>standard targets of LDL-C &lt; 100 mg/dL and BP &lt; 130/85 mm Hg</description>
        </group>
        <group group_id="B2">
          <title>Aggressive Treatment</title>
          <description>/aggressive targets of LDL-C &lt; 70 mg/dL plus BP &lt; 115/75 mm Hg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="247"/>
            <count group_id="B2" value="252"/>
            <count group_id="B3" value="499"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.9" spread="4.24"/>
                    <measurement group_id="B2" value="55.3" spread="4.24"/>
                    <measurement group_id="B3" value="56.1" spread="4.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="163"/>
                    <measurement group_id="B2" value="164"/>
                    <measurement group_id="B3" value="327"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changing LDL Cholesterol</title>
        <description>LDL cholesterol intervention to lower targets than are currently recommended to retard atherosclerosis measured by LDL-C mg/dL.&#xD;
Scale: LDL cholesterol levels should be less than 100 mg/dL</description>
        <time_frame>36 months</time_frame>
        <population>Native American</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment</title>
            <description>standard targets of LDL-C &lt; 100 mg/dL and</description>
          </group>
          <group group_id="O2">
            <title>Aggressive Treatment</title>
            <description>/aggressive targets of LDL-C &lt; 70 mg/dL</description>
          </group>
        </group_list>
        <measure>
          <title>Changing LDL Cholesterol</title>
          <description>LDL cholesterol intervention to lower targets than are currently recommended to retard atherosclerosis measured by LDL-C mg/dL.&#xD;
Scale: LDL cholesterol levels should be less than 100 mg/dL</description>
          <population>Native American</population>
          <units>Mg/dl</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="252"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" spread="74"/>
                    <measurement group_id="O2" value="70" spread="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changing Blood Pressure</title>
        <description>Treatment of blood pressure to prevent/reduce diseases of heart and blood vessels. Measured by mmHG.&#xD;
Normal values should be below 120/80 mm Hg.</description>
        <time_frame>36 month follow-up</time_frame>
        <population>American Indian</population>
        <group_list>
          <group group_id="O1">
            <title>SANDS Control Group</title>
            <description>Standard Treatment for blood pressure</description>
          </group>
          <group group_id="O2">
            <title>SANDS Intervention Group</title>
            <description>FDA approved drugs to treat blood pressure</description>
          </group>
        </group_list>
        <measure>
          <title>Changing Blood Pressure</title>
          <description>Treatment of blood pressure to prevent/reduce diseases of heart and blood vessels. Measured by mmHG.&#xD;
Normal values should be below 120/80 mm Hg.</description>
          <population>American Indian</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="252"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130" spread=".001"/>
                    <measurement group_id="O2" value="115" spread=".001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SANDS Control Group</title>
          <description>Standard Treatment for blood pressure and cholesterol</description>
        </group>
        <group group_id="E2">
          <title>SANDS Intervention Group</title>
          <description>FDA approved drugs to treat blood pressure and cholesterol</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Heart Attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Barbara V Howard</name_or_title>
      <organization>MedStar Research Institute</organization>
      <phone>301-560-7305</phone>
      <email>barbara.v.howard@medstar.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

